Literature DB >> 27650363

Afatinib in lung cancer harboring EGFR mutation in the LUX-Lung trials: six plus three is greater than seven?

Tetsuya Mitsudomi1, Yoshihisa Kobayashi1.   

Abstract

Entities:  

Year:  2016        PMID： 27650363      PMCID： PMC5009085          DOI： 10.21037/tlcr.2016.07.06

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

1.  Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): analysis of overall survival data from two randomised, phase 3 trials.

Authors:  James Chih-Hsin Yang; Yi-Long Wu; Martin Schuler; Martin Sebastian; Sanjay Popat; Nobuyuki Yamamoto; Caicun Zhou; Cheng-Ping Hu; Kenneth O'Byrne; Jifeng Feng; Shun Lu; Yunchao Huang; Sarayut L Geater; Kye Young Lee; Chun-Ming Tsai; Vera Gorbunova; Vera Hirsh; Jaafar Bennouna; Sergey Orlov; Tony Mok; Michael Boyer; Wu-Chou Su; Ki Hyeong Lee; Terufumi Kato; Dan Massey; Mehdi Shahidi; Victoria Zazulina; Lecia V Sequist
Journal:  Lancet Oncol       Date:  2015-01-12       Impact factor: 41.316

2.  Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): a phase 2B, open-label, randomised controlled trial.

Authors:  Keunchil Park; Eng-Huat Tan; Ken O'Byrne; Li Zhang; Michael Boyer; Tony Mok; Vera Hirsh; James Chih-Hsin Yang; Ki Hyeong Lee; Shun Lu; Yuankai Shi; Sang-We Kim; Janessa Laskin; Dong-Wan Kim; Catherine Dubos Arvis; Karl Kölbeck; Scott A Laurie; Chun-Ming Tsai; Mehdi Shahidi; Miyoung Kim; Dan Massey; Victoria Zazulina; Luis Paz-Ares
Journal:  Lancet Oncol       Date:  2016-04-12       Impact factor: 41.316

3.  Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial.

Authors:  Tetsuya Mitsudomi; Satoshi Morita; Yasushi Yatabe; Shunichi Negoro; Isamu Okamoto; Junji Tsurutani; Takashi Seto; Miyako Satouchi; Hirohito Tada; Tomonori Hirashima; Kazuhiro Asami; Nobuyuki Katakami; Minoru Takada; Hiroshige Yoshioka; Kazuhiko Shibata; Shinzoh Kudoh; Eiji Shimizu; Hiroshi Saito; Shinichi Toyooka; Kazuhiko Nakagawa; Masahiro Fukuoka
Journal:  Lancet Oncol       Date:  2009-12-18       Impact factor: 41.316

4.  Afatinib versus placebo for patients with advanced, metastatic non-small-cell lung cancer after failure of erlotinib, gefitinib, or both, and one or two lines of chemotherapy (LUX-Lung 1): a phase 2b/3 randomised trial.

Authors:  Vincent A Miller; Vera Hirsh; Jacques Cadranel; Yuh-Min Chen; Keunchil Park; Sang-We Kim; Caicun Zhou; Wu-Chou Su; Mengzhao Wang; Yan Sun; Dae Seog Heo; Lucio Crino; Eng-Huat Tan; Tsu-Yi Chao; Mehdi Shahidi; Xiuyu Julie Cong; Robert M Lorence; James Chih-Hsin Yang
Journal:  Lancet Oncol       Date:  2012-03-26       Impact factor: 41.316

5.  Afatinib versus cisplatin plus gemcitabine for first-line treatment of Asian patients with advanced non-small-cell lung cancer harbouring EGFR mutations (LUX-Lung 6): an open-label, randomised phase 3 trial.

Authors:  Yi-Long Wu; Caicun Zhou; Cheng-Ping Hu; Jifeng Feng; Shun Lu; Yunchao Huang; Wei Li; Mei Hou; Jian Hua Shi; Kye Young Lee; Chong-Rui Xu; Dan Massey; Miyoung Kim; Yang Shi; Sarayut L Geater
Journal:  Lancet Oncol       Date:  2014-01-15       Impact factor: 41.316

Review 6.  Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.

Authors:  Tetsuya Mitsudomi; Yasushi Yatabe
Journal:  Cancer Sci       Date:  2007-09-20       Impact factor: 6.716

7.  BIBW2992, an irreversible EGFR/HER2 inhibitor highly effective in preclinical lung cancer models.

Authors:  D Li; L Ambrogio; T Shimamura; S Kubo; M Takahashi; L R Chirieac; R F Padera; G I Shapiro; A Baum; F Himmelsbach; W J Rettig; M Meyerson; F Solca; H Greulich; K-K Wong
Journal:  Oncogene       Date:  2008-04-14       Impact factor: 9.867

8.  Final overall survival results from a randomised, phase III study of erlotinib versus chemotherapy as first-line treatment of EGFR mutation-positive advanced non-small-cell lung cancer (OPTIMAL, CTONG-0802).

Authors:  C Zhou; Y L Wu; G Chen; J Feng; X-Q Liu; C Wang; S Zhang; J Wang; S Zhou; S Ren; S Lu; L Zhang; C Hu; C Hu; Y Luo; L Chen; M Ye; J Huang; X Zhi; Y Zhang; Q Xiu; J Ma; L Zhang; C You
Journal:  Ann Oncol       Date:  2015-07-03       Impact factor: 32.976

9.  Collateral chemoresistance to anti-microtubule agents in a lung cancer cell line with acquired resistance to erlotinib.

Authors:  Hiroshi Mizuuchi; Kenichi Suda; Katsuaki Sato; Shuta Tomida; Yoshihiko Fujita; Yoshihisa Kobayashi; Yoshihiko Maehara; Yoshitaka Sekido; Kazuto Nishio; Tetsuya Mitsudomi
Journal:  PLoS One       Date:  2015-04-14       Impact factor: 3.240

10.  The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients.

Authors:  Shang-Gin Wu; Yi-Nan Liu; Meng-Feng Tsai; Yih-Leong Chang; Chong-Jen Yu; Pan-Chyr Yang; James Chih-Hsin Yang; Yueh-Feng Wen; Jin-Yuan Shih
Journal:  Oncotarget       Date:  2016-03-15
View more
  3 in total

1.  Itaconic acid hybrids as potential anticancer agents.

Authors:  Ivana Perković; Maja Beus; Dominique Schols; Leentje Persoons; Branka Zorc
Journal:  Mol Divers       Date:  2020-10-11       Impact factor: 3.364

2.  A Retrospective Comparison of the Clinical Efficacy of Gefitinib, Erlotinib, and Afatinib in Japanese Patients With Non-Small Cell Lung Cancer.

Authors:  Atsushi Fujiwara; Masamichi Yoshida; Hajime Fujimoto; Hiroki Nakahara; Kentaro Ito; Kota Nishihama; Taro Yasuma; Osamu Hataji; Osamu Taguchi; Corina N D'Alessandro-Gabazza; Esteban C Gabazza; Tetsu Kobayashi
Journal:  Oncol Res       Date:  2018-01-10       Impact factor: 5.574

3.  Targeting USP13-mediated drug tolerance increases the efficacy of EGFR inhibition of mutant EGFR in non-small cell lung cancer.

Authors:  Philippe Giron; Carolien Eggermont; Amir Noeparast; Hugo Vandenplas; Erik Teugels; Ramses Forsyth; Olivier De Wever; Pedro Aza-Blanc; Gustavo J Gutierrez; Jacques De Grève
Journal:  Int J Cancer       Date:  2020-11-19       Impact factor: 7.396
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.